Hangzhou Tigermed Consulting Co., Ltd
300347
Rang in Aktien
#3217
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
Aktienkurs
$7.44
Marktkapitalisierung
$5.49B
Veränderung (1 Tag)
-2.99%
Veränderung (1 Jahr)
-0.42%
Land
CN
Handel Hangzhou Tigermed Consulting Co., Ltd (300347)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Hangzhou Tigermed Consulting Co., Ltd (300347)
Anzahl der ausstehenden Aktien zum June 2026: 836.35M
Laut den neuesten Finanzberichten und dem Aktienkurs von Hangzhou Tigermed Consulting Co., Ltd beträgt die aktuelle Anzahl der ausstehenden Aktien 836.35M. Am Ende von December 2024 hatte das Unternehmen 863.04M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Hangzhou Tigermed Consulting Co., Ltd (300347) von 2009 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 836.35M | -2.04% |
| 2025 | 853.74M | -1.08% |
| 2024 | 863.04M | -0.22% |
| 2023 | 864.95M | -0.69% |
| 2022 | 870.96M | 9.01% |
| 2020 | 798.98M | 7.27% |
| 2019 | 744.81M | -0.63% |
| 2018 | 749.50M | 1.26% |
| 2017 | 740.14M | 5.24% |
| 2016 | 703.26M | 8.00% |
| 2015 | 651.16M | 0.30% |
| 2014 | 649.23M | 1.26% |
| 2013 | 641.15M | 20.16% |
| 2012 | 533.60M | 10.72% |
| 2011 | 481.93M | 1.32% |
| 2010 | 475.64M | 16.86% |
| 2009 | 407.01M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | -69.64% |
US
|
|
| 396.00M | -52.65% |
US
|
|
| 478.91M | -42.74% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.19M | -92.56% |
NL
|
